nVerses Capital’s Keros Therapeutics KROS Stock Holding History

nVerses Capital’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$140K	Buy	+13,124	New	+$146K	0.22%	223

Other funds holding KROS

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

EWA

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

nVerses Capital's KROS Position: Q2 2026 in Review

nVerses Capital opened a new position in Keros Therapeutics (KROS) in Q2 2026: 13,124 shares worth $140K. The stake represents 0.22% of the portfolio and ranks #223 among its holdings.

23 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

nVerses Capital held 13,124 shares of Keros Therapeutics worth $140K as of Q2 2026.
Keros Therapeutics was a new nVerses Capital position in Q2 2026.
Keros Therapeutics made up 0.22% of nVerses Capital's portfolio in Q2 2026, its #223 holding.
23 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.